Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
48 /100
MEDIUM RISK
Score updated Aug 06, 2026

ENTX — Entera Bio Ltd. Dilution Risk Tracker

Track ENTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ENTX — Get alerts when the score changes →

As of August 06, 2026, Entera Bio Ltd. (ENTX) has a DilutionWatch DilutionScore of 48/100, rated MEDIUM dilution risk. Entera Bio Ltd. has 49.23M shares outstanding, 27 institutional holders tracked. Key dilution vectors include 546.0K outstanding warrants, approximately 6 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
65
📊 Float Risk
7
⚠️ Warrant Exposure
15
🔄Convertible Debt—

Dilution Forecast

☀️
Clear
No significant dilution signals
7%
💰 Capital Raise 15%
• Under 12 months cash (6mo)
🔔 Track ENTX — Get forecast alerts →

Market Data

Market CapN/A
Shares Outstanding49.23M
Float31.37M
Cash$4.14M
DebtN/A
Short InterestN/A

Institutional Holdings

QoQ: ↓ 12.8% shares (2026Q1 vs prior)
27 institutional holders · 8.04M shares
#1 Knoll Capital Management, LLC 5.88M shares
#2 RENAISSANCE TECHNOLOGIES LLC 473.4K shares
#3 Seven Fleet Capital Management LP 340.9K shares
+ 17 more holders Sign up free to view →

Short Interest

Short Interest297.5K
Days to Cover1.3
% of Float0.9%
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
EFFECT EFFECT 2026-05-15
4 INSIDER TRANSACTION 2026-05-08
4 INSIDER TRANSACTION 2026-05-08
8-K 8K EVENT 2026-05-08
Full SEC filing analysis available with free account →

Recent News

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on P GlobeNewswire · Aug 04
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference GlobeNewswire · Jul 31
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement Yahoo Finance · Jul 27

What This Means for ENTX Shareholders

Entera Bio Ltd. (ENTX) has a DilutionScore of 48/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of August 06, 2026.

DilutionWatch tracks 546,028 outstanding warrants for ENTX. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: ENTX has approximately 6 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for ENTX in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch shows real-time score changes for ENTX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →

Understanding ENTX's Dilution Risk Factors

Primary Risk Drivers

The most significant dilution risk factors for Entera Bio Ltd. are Offering Ability and Cash Runway. Offering Ability scores at a moderate level, indicating the company has the capacity to raise capital through new equity offerings, which inherently increases share count. Cash Runway is also elevated at a concerning level, reflecting that the company's cash reserves are insufficient to sustain operations for more than six months. This creates urgency for capital raising, increasing the risk of dilution. These two factors together suggest that the company may need to issue new shares soon to maintain operations, directly impacting existing shareholders.

Factors Currently Not a Concern

Float Risk and Warrant Exposure are currently low, indicating minimal dilution from outstanding warrants or a large public float. Float Risk at a low level suggests that the current share distribution is not heavily diluted by a large number of publicly traded shares. Warrant Exposure also remains low, meaning there is limited potential for additional shares to be issued through warrant exercises. A change in either could raise risk if new warrants are issued or if a significant portion of shares becomes available for trading.

SEC Filings to Watch

Several SEC filings should be monitored closely for signs of increased dilution. An S-3 registration statement would signal an intent to register securities for future sale, potentially leading to new share issuance. A 424B5 filing indicates a planned offering and could precede a capital raise. An 8-K Item 1.01 event may report a material agreement or transaction that could involve equity issuance. Additionally, a 10-Q filing might reveal changes in cash position or strategic plans that suggest the company is preparing for additional financing.

How Dilution Happens

Dilution occurs when new shares are issued to raise capital. If Entera Bio Ltd. needs to fund operations and issues new shares, existing shareholders' ownership percentage decreases. For example, if Offering Ability is high and the company raises funds through a new equity offering, the number of outstanding shares increases. This directly reduces the value per share for current investors. If Cash Runway is low, the urgency to raise capital increases, making dilution more likely. Convertible notes may also convert into shares, further increasing supply and reducing ownership percentage.

What Would Make This Worse

The risk profile could deteriorate significantly if the company begins issuing convertible notes or warrants with favorable conversion terms, leading to a spike in potential share issuance. Additionally, if the cash runway continues to decline and the company is forced to raise capital through multiple offerings, dilution would compound. If Offering Ability increases due to new strategic partnerships or financing commitments, it could signal an imminent large-scale equity issuance, greatly increasing risk for existing shareholders.

Key Insight

Low scores indicate safer conditions; a score of zero means no risk. A high Cash Runway score signals operational stress, which may prompt capital raising and thus dilution.

How to Monitor ENTX for Dilution Risk

What This Risk Level Means

For an operating company like Entera Bio Ltd. (ENTX), a medium dilution risk score indicates that while the company is not currently in immediate peril, it has notable exposure to potential dilution events. As a company with ongoing operations, ENTX must balance its capital needs with maintaining shareholder value, and this balance is precarious at current levels. Medium risk suggests that although the company's equity structure is stable, there are enough factors present—such as upcoming convertible notes or potential financing rounds—that could lead to dilution if not carefully managed.

What Typically Happens Next

Companies with a profile similar to ENTX often proceed through capital-raising activities such as shelf registrations or ATM programs, which allow them to issue equity on demand. These mechanisms are common for companies in growth phases or those needing flexibility in funding. Additionally, warrant exercises and convertible note conversions may occur within 12–24 months, depending on the terms of issued securities. Monitoring these timelines is essential, as they often precede significant dilution events.

Monitoring Playbook

To effectively track ENTX using DilutionWatch, set up alerts for any changes in key risk factors such as Offering Ability or Cash Runway. Check scores weekly, particularly around earnings releases and SEC filing dates. When thresholds are crossed—such as a sudden rise in Offering Ability or an increase in Convertible Note Risk—review the company’s recent filings and capital structure updates. Use Shelf & ATM Monitor to track any new equity offerings or financing activities.

Early Warning Signals

Any sudden spike in Offering Ability or a drop in Cash Runway may indicate that the company is preparing for a capital raise. A change in convertible note terms, such as a conversion price reduction or maturity extension, also signals increased dilution risk. Additionally, if the company files for a shelf registration or announces an ATM program, this can be a strong indicator of upcoming equity issuance.

What a Positive Resolution Looks Like

A positive resolution would involve a capital raise that improves cash runway and reduces reliance on dilutive financing. Paying down debt or having warrants expire without exercise would also help lower the risk profile. If convertible notes are refinanced at better terms, or if the company enters into a strategic partnership that provides non-dilutive funding, these actions would significantly improve the company's dilution outlook.

Watch For

Any filing related to new equity issuance, convertible note conversions, or warrant exercises as early indicators of rising dilution risk.

Full SEC filing analysis available with free account  →
Track ENTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ENTX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

AAT AHRT ALOT AMPH AMPY

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for ENTX
ENTX FDA Catalyst Timeline & Biotech Grade — BiotechSignsENTX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.